To evaluate the disease severity of Psoriasis using blood samples.
Not Applicable
- Conditions
- Health Condition 1: L40-L45- Papulosquamous disorders
- Registration Number
- CTRI/2021/01/030667
- Lead Sponsor
- Father Muller Medical College
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
All patients clinically diagnosed to have psoriasis
Healthy volunteers
Exclusion Criteria
Individuals with other pre-existing skin disorders
Individuals already on IL-17 inhibitors
Individuals not willing to participate in the study
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method If IL-17A levels 3.9 ng/ml , significantTimepoint: Il-17 levels and severity of skin lesions using Psoriasis area severity index will be assessed at single visit.
- Secondary Outcome Measures
Name Time Method Whether IL-17 values truly reflect the severity of psoriasis in an individual.Timepoint: The severity of psoriasis and IL-17 level will be assessed on a single visit only.